vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $170.6M, roughly 1.1× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 33.3%, a 43.9% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 9.8%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
DOCS vs PTGX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $170.6M |
| Net Profit | $61.6M | $131.7M |
| Gross Margin | 89.9% | — |
| Operating Margin | 38.9% | 74.3% |
| Net Margin | 33.3% | 77.2% |
| Revenue YoY | 9.8% | 184.4% |
| Net Profit YoY | -18.1% | 381.7% |
| EPS (diluted) | $0.31 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $145.9M | — | ||
| Q1 25 | $138.3M | — | ||
| Q4 24 | $168.6M | $170.6M | ||
| Q3 24 | $136.8M | — | ||
| Q2 24 | $126.7M | — | ||
| Q1 24 | $118.1M | $255.0M |
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | — | ||
| Q2 25 | $53.3M | — | ||
| Q1 25 | $62.5M | — | ||
| Q4 24 | $75.2M | $131.7M | ||
| Q3 24 | $44.2M | — | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $40.6M | $207.3M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | — | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 37.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 47.4% | 74.3% | ||
| Q3 24 | 38.8% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 35.5% | 80.9% |
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 36.5% | — | ||
| Q1 25 | 45.2% | — | ||
| Q4 24 | 44.6% | 77.2% | ||
| Q3 24 | 32.3% | — | ||
| Q2 24 | 32.7% | — | ||
| Q1 24 | 34.4% | 81.3% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | — | ||
| Q2 25 | $0.27 | — | ||
| Q1 25 | $0.31 | — | ||
| Q4 24 | $0.37 | $2.01 | ||
| Q3 24 | $0.22 | — | ||
| Q2 24 | $0.21 | — | ||
| Q1 24 | $0.20 | $3.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $675.3M |
| Total Assets | $1.2B | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | — | ||
| Q3 25 | $169.2M | — | ||
| Q2 25 | $137.3M | — | ||
| Q1 25 | $209.6M | — | ||
| Q4 24 | $165.3M | $418.9M | ||
| Q3 24 | $184.2M | — | ||
| Q2 24 | $111.4M | — | ||
| Q1 24 | $96.8M | $322.6M |
| Q4 25 | $979.3M | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.0B | $675.3M | ||
| Q3 24 | $961.2M | — | ||
| Q2 24 | $913.6M | — | ||
| Q1 24 | $901.4M | $560.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.2B | $744.7M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | $629.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $184.2M |
| Free Cash FlowOCF − Capex | — | $182.8M |
| FCF MarginFCF / Revenue | — | 107.1% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 0.99× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | — | ||
| Q3 25 | $93.9M | — | ||
| Q2 25 | $62.1M | — | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $65.2M | $184.2M | ||
| Q3 24 | $68.3M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $63.9M | $-27.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-27.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | 0.1% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | 1.40× | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
PTGX
Segment breakdown not available.
